NCT04185090View on ClinicalTrials.gov

To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 29, 2020

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
HypertensionDyslipidemias
Interventions
COMBINATION_PRODUCT

ID1803

Amlodipine 10mg/Valsartan 160mg

COMBINATION_PRODUCT

ID1801

Ezetimibe 10mg/Rosuvastatin Ca 20.8mg

COMBINATION_PRODUCT

ID1803+ID1801

Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT04185090 - To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults | Biotech Hunter | Biotech Hunter